<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314833</url>
  </required_header>
  <id_info>
    <org_study_id>MASTER</org_study_id>
    <nct_id>NCT01314833</nct_id>
  </id_info>
  <brief_title>Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy</brief_title>
  <official_title>Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in HER2-negative Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Anti-Cancer Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aimed to evaluate the noninferiority of short-term anthracycline-free chemotherapy (TC,
      six cycles of docetaxel and cyclophosphamide) or short-term anthracycline-based chemotherapy
      (CEF-T, three cycles of cyclophosphamide/epirubicin/fluorouracil followed by three cycles of
      docetaxel) to a standard anthracycline/taxane-containing chemotherapy (EC-P, epirubicin, and
      cyclophosphamide for four cycles followed by paclitaxel for twelve weeks) in HER2-negative
      operable breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was initiated as an adjuvant chemotherapy trial to test noninferiority of an
      anthracycline-free short-term regimen (T75C600 x 6 [TC] once every 3 weeks) or a short-term
      regimen (C500E100F500 x 3 once every 3 weeks followed by T100 x 3 every 3 weeks [CEF-T])
      compared with a standard long-term anthracycline-containing regimen (E90C600 x 4 once every 3
      weeks followed by P80 x 12 once every week [EC-P]) in HER2-negative breast cancer. Patients
      were randomly assigned (1:1:1) to each arm after completing the surgical excision of the
      primary tumor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2010</start_date>
  <completion_date type="Actual">June 15, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as the time from randomization to occurrence of a new event including local recurrence, regional relapse, distant metastasis, contralateral primary breast cancer, second non-breast invasive cancer (excluding non-melanoma skin cancers), or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant Disease-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as the time from randomization to the earliest recurrence outside of the ipsilateral locoregional region or to death from any cause, whenever a death occurred before distant recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>defined as the time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>through chemotherapy completion, an average of 6 months</time_frame>
    <description>Number of Participants with Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1570</enrollment>
  <condition>Primary Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TC*6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CEF*3-T*3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EC*4-wP*12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel Cyclophosphamide</intervention_name>
    <description>Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1
1 cycle = 21 days
TC*6</description>
    <arm_group_label>TC*6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide Fluorouracil Epirubicin Docetaxel</intervention_name>
    <description>1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1
1 cycle = 21 days
4th-6th Cycle: Docetaxel 100mg/m² D1
1 cycle = 21 days CEF*3-T*3</description>
    <arm_group_label>CEF*3-T*3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin Cyclophosphamide Paclitaxel</intervention_name>
    <description>1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1
1 cycle = 21 days
5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15
1 cycle = 21 days EC*4-P*4</description>
    <arm_group_label>EC*4-wP*12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients, age at diagnosis 18 - 75 years

          -  Histological confirmed unilateral primary invasive carcinoma of the breast

          -  Adequate surgical treatment with complete resection of the tumor (R0) and resection of
             &gt; or = 10 axillary nodes or SLN in clinically N0 patients

          -  Node positive disease or node-negative disease with at least one other risk factor
             (tumor size &gt; or = 2 cm, grade &gt; or = II)

          -  HER2-negative disease

          -  No evidence for distant metastasis (M0) after conventional staging

          -  Performance Status ECOG &lt; or = 1

          -  The patient must be accessible for treatment and follow-up

          -  LVEF&gt; 50%

          -  Negative pregnancy test (urine or serum) within 7 days prior to randomization in
             premenopausal patients

          -  Leucocytes &gt; or = 4 x 10^9/L

          -  platelets &gt; or = 100 x 10^9/L

          -  haemoglobin &gt; or = 9 g/dL

          -  total bilirubin &lt; or = 1.5 UNL

          -  ASAT (SGOT) and ALAT (SGPT) &lt; or = 2.5 UNL

          -  creatinine &lt; 175 mmol/L (2 mg/dL)

        Exclusion Criteria:

          1. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy
             or endocrine therapy）;

          2. Has bilateral breast cancer;

          3. Has the previous history of additional malignancy, with the exception of adequately
             treated basal cell carcinoma and cervical carcinoma in situ.

          4. Has metastatic (Stage 4) breast cancer;

          5. Has any &gt;T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and
             inflammatory breast cancer);

          6. Is pregnant, is breastfeeding women, or women of childbearing age who cannot practice
             effective contraceptives;

          7. Patients participating in other clinical trials at the same time;

          8. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left
             ventricular ejection fraction (LVEF) &lt; 50% (cardiac ultrasound); severe cardio
             cerebral vascular disease within the 6 months previous of randomization (such as
             unstable angina, chronic heart failure, uncontrolled hypertension with blood
             pressure&gt;150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic
             patients with poor blood glucose control; patients with severe hypertension;

          9. Has known allergy to taxane and excipients;

         10. Has severe or uncontrolled infection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar 10;27(8):1177-83. doi: 10.1200/JCO.2008.18.4028. Epub 2009 Feb 9.</citation>
    <PMID>19204201</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Luminal A</keyword>
  <keyword>Luminal B</keyword>
  <keyword>TNBC</keyword>
  <keyword>DFS</keyword>
  <keyword>DDFS</keyword>
  <keyword>OS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

